DE69837542T2 - Ldl-rezeptor - Google Patents

Ldl-rezeptor Download PDF

Info

Publication number
DE69837542T2
DE69837542T2 DE69837542T DE69837542T DE69837542T2 DE 69837542 T2 DE69837542 T2 DE 69837542T2 DE 69837542 T DE69837542 T DE 69837542T DE 69837542 T DE69837542 T DE 69837542T DE 69837542 T2 DE69837542 T2 DE 69837542T2
Authority
DE
Germany
Prior art keywords
lrp5
sequence
polypeptide
nucleic acid
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837542T
Other languages
German (de)
English (en)
Other versions
DE69837542D1 (de
Inventor
John Andrew Coton TODD
John Wilfred Lansdale HESS
Charles Thomas Houston CASKEY
Roger David Cox
David Lansdale GERHOLD
Holly Telford HAMMOND
Patricia Lansdale HEY
Yoshihiko Kawaguchi
Tony Raymond Merriman
Michael Lee Houston METZKER
Yusuke Osaka NAKAGAWA
Michael Sean Lansdale PHILLIPS
Rebecca Christina Twells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69837542D1 publication Critical patent/DE69837542D1/de
Publication of DE69837542T2 publication Critical patent/DE69837542T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
DE69837542T 1997-04-15 1998-04-15 Ldl-rezeptor Expired - Lifetime DE69837542T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4355397P 1997-04-15 1997-04-15
US43553P 1997-04-15
US4874097P 1997-06-05 1997-06-05
US48740P 1997-06-05
PCT/GB1998/001102 WO1998046743A1 (en) 1997-04-15 1998-04-15 Novel ldl-receptor

Publications (2)

Publication Number Publication Date
DE69837542D1 DE69837542D1 (de) 2007-05-24
DE69837542T2 true DE69837542T2 (de) 2008-01-31

Family

ID=26720554

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837542T Expired - Lifetime DE69837542T2 (de) 1997-04-15 1998-04-15 Ldl-rezeptor

Country Status (9)

Country Link
US (1) US6545137B1 (enExample)
EP (1) EP0988379B1 (enExample)
JP (1) JP4271735B2 (enExample)
AT (1) ATE359367T1 (enExample)
AU (1) AU733722B2 (enExample)
CA (1) CA2286313C (enExample)
DE (1) DE69837542T2 (enExample)
ES (1) ES2285767T3 (enExample)
WO (1) WO1998046743A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244577B2 (en) * 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
FR2798138B1 (fr) * 1999-09-03 2004-05-21 Centre Nat Rech Scient Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante
AU2000256269B2 (en) * 2000-04-05 2006-11-02 Creighton University The high bone mass gene of 11q13.3
CA2410253C (en) * 2000-05-26 2010-06-15 Genome Therapeutics Corporation Regulating lipid levels via the zmax1 or hbm gene
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
JP2004505894A (ja) 2000-06-02 2004-02-26 ユニバーシティー　オブ　コネティカット　ヘルス　センター 免疫療法のためのα（２）マクログロブリンと抗原分子との複合体
AU2001295010A1 (en) * 2000-08-18 2002-03-04 Case Western Reserve University Regulator gene and system useful for the diagnosis and therapy of osteoporosis
WO2002074906A2 (en) * 2001-03-16 2002-09-26 Eli Lilly And Company Lp mammalian proteins; related reagents
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
AU2002316095A1 (en) * 2001-05-11 2002-11-25 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels
US20040221326A1 (en) * 2001-05-11 2004-11-04 Philip Babij Transgenic animal model of bone mass modulation
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
AU2002342734B2 (en) * 2001-05-17 2007-07-26 Oscient Pharmaceuticals Corporation Reagents and methods for modulating Dkk-mediated interactions
WO2003015712A2 (en) 2001-08-20 2003-02-27 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin
GB2381790A (en) * 2001-09-26 2003-05-14 Glaxo Group Ltd LDL-receptor polypeptides
JP2005220022A (ja) * 2002-03-08 2005-08-18 Anges Mg Inc Ｗｎｔの新規作用、及び、疾患治療への応用
US7169559B2 (en) * 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
US20030219793A1 (en) * 2002-10-04 2003-11-27 Carulli John P. High bone mass gene of 11q13.3
US7473770B2 (en) 2003-11-17 2009-01-06 Merck & Co., Inc. Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
WO2005049640A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
US20080227734A1 (en) * 2003-11-24 2008-09-18 Gunnar Westin Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2013067355A1 (en) 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
MX2019014331A (es) 2017-05-31 2020-01-27 Boehringer Ingelheim Int Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU1173995A (en) * 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
WO1995030774A1 (en) * 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
ES2169804T3 (es) * 1995-06-23 2002-07-16 Us Gov Health & Human Serv Actividad despigmentante de la proteina señal aguti y peptidos de la misma.
AU2000256269B2 (en) 2000-04-05 2006-11-02 Creighton University The high bone mass gene of 11q13.3

Also Published As

Publication number Publication date
WO1998046743A1 (en) 1998-10-22
EP0988379B1 (en) 2007-04-11
CA2286313C (en) 2011-01-11
AU7061498A (en) 1998-11-11
US6545137B1 (en) 2003-04-08
EP0988379A1 (en) 2000-03-29
DE69837542D1 (de) 2007-05-24
ATE359367T1 (de) 2007-05-15
ES2285767T3 (es) 2007-11-16
CA2286313A1 (en) 1998-10-22
JP4271735B2 (ja) 2009-06-03
JP2002501376A (ja) 2002-01-15
AU733722B2 (en) 2001-05-24

Similar Documents

Publication Publication Date Title
DE69837542T2 (de) Ldl-rezeptor
DE69631540T2 (de) Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs-suszeptilitaetsgens brca2 und dessen anwendungen
DE69626132T2 (de) Regulierung von essgewohnheiten
DE69819345T2 (de) Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
DE69926729T2 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
DE69838905T2 (de) Transkriptionsfaktor islet-brain 1 (ib1)
DE10294485T5 (de) Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind
DE69636870T2 (de) KVLQT1 - EIN GEN DES LONG-QT-SYNDROMS, WELCHES FÜR KVLQT1 KODIERT UND WELCHES SICH MIT Mink ZUSAMMENSETZT, UM Iks-KALIUMKANÄLE DES HERZENS ZU BILDEN
DE60128830T2 (de) Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
US7244577B2 (en) Method of screening for modulator of LRP5 activity
DE69635751T2 (de) "long qt" gene und methode zur diagnose oder prävention des "long qt" syndroms
DE60129433T2 (de) Regulation des lipidniveaus über die gene zmax1 oder hbm
US6555654B1 (en) LDL-receptor
DE60037126T2 (de) POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE
DE60029791T2 (de) Rezeptor eines neurotrophen faktors (gfr-alpha-4)
DE69931345T2 (de) Gen, welches für neues transmembranprotein kodiert
DE10004815B4 (de) Menschliche intestinale Natriumphosphat-Kotransporter
DE69936781T2 (de) Kvlqt1 - im zusammenhang mit 'long qt syndrom'
DE60036548T2 (de) Neue kalium-kanäle und dafür kodierende gene
DE69833189T2 (de) Nukleinsäuresequenzen für atp-bindungs cassette-transporter
DE60123109T2 (de) Mit schizophrenie in zusammenhang stehendes gen, das für ein potential-abhängiges ionkanal kodiert
DE60026569T2 (de) Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen
DE60024862T2 (de) "insulinabhängiges sequenz dna bindendes protein-1" (irsdbp-1), dafür kodierendes gen und ihre verwendungen
DE60217081T2 (de) Gen beteiligt an v(d)j rekombination und/oder dna reparatur
DE60038025T2 (de) Hochaffinitäts-cholintransporter

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO, INC., RAHWAY, N.J., US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

8328 Change in the person/name/address of the agent

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LUXEMBOURG, LU

R081 Change of applicant/patentee

Ref document number: 988379

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 988379

Country of ref document: EP

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

Effective date: 20121213